<h2 style="text-align:center">Adopting Oncology Biosimilars Into Clinical Practice: How Pharmacists Can Help Pave the Way</h2>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by educational grants from 
Amgen and Coherus BioSciences, Inc.</div>
 
Faculty Presenters 
 
Julie Kennerly-Shah, PharmD, MS, MHA, BCPS 
Associate Director 
Department of Pharmacy 
The Ohio State University Comprehensive Cancer Center 
Columbus, Ohio 
 
Raj Duggal, PharmD, BCOP 
Clinical Manager, Oncology Pharmacy Services 
Indiana University Health 
Indianapolis, Indiana 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
With the increasing availability of biosimilars for therapeutic and supportive care oncology biologics, pharmacists need to orient clinicians about the implementation of these agents into clinical practice and be prepared to address and overcome concerns or challenges. Identifying and dispelling common misbeliefs leading toward hesitancy about oncology biosimilars is the first step pharmacists must trounce. To accurately educate other health care professionals, pharmacists must be well versed in the regulatory approval process, efficacy and safety data, and nuances of interchangeability and substitution for biosimilars compared with their reference biologics. By harnessing their medication expertise and through the approaches identified in this program, pharmacists can help to lead education to patients and fellow health care team members and facilitate the successful implementation of oncology biosimilars into clinical practice. 
 
Target Audience:&nbsp;Specialty, oncology, and health-system pharmacists 
Type of Activity:&nbsp;Application 
Release date: October 23, 2020 
Expiration date: April 23, 2021 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Explain the difference between the FDA approval process for a biosimilar product and the FDA approval process for that of an originator biologic</li>
	<li>Compare the FDA-approved indications for biosimilars that are currently available, as well as those that may reach the market soon, with their originator biologics</li>
	<li>Differentiate the challenges that affect the implementation of oncology biosimilars in clinical practice</li>
	<li>Apply knowledge of the challenges associated with the adoption of biosimilars into clinical practice to a real-world patient and clinician counseling scenario</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-319-H01-P. The activity is available for CE credit through April 23, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Julie Kennerly-Shah, PharmD, MS, MHA, BCPS, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultant: Celgene Corporation, Clovis Oncology, Genentech, Kyowa Kirin, Immunomedics, Omeros</li>
</ul>
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Raj Duggal, PharmD, BCOP 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Kelly McCormick; Susan Pordon; and Brianna Winters 
 
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Adopting Oncology Biosimilars Into Clinical Practice: How Pharmacists Can Help Pave the Way

<img src="https://s3.amazonaws.com/ptce/_media/_image/Biosimilars_logo.png" style="max-width:350px; width:100%" />

<h2 style="text-align:center">Biosimilars: A Managed Care Update of Real-World Evidence and Cost-Savings Data When Treating Inflammatory Conditions</h2>

<div style="text-align:center">A 1-hour Enduring Broadcast! 
&nbsp;</div>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Sandoz, Inc., a Novartis Division.</div>
 
Faculty Presenter 
 
Sonia T. Oskouei, PharmD, BCMAS, DPLA 
Vice President, Biosimilars 
Cardinal Health 
Atlanta, Georgia 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
It is estimated that inflammatory disease affects between 5% and 7% of the global population. Anti-tumor necrosis factor (anti-TNF) drugs have experienced widespread use to prevent joint damage in rheumatic and immune-mediated inflammatory diseases but are associated with increasing costs that restrict patient access to treatment. Biosimilar agents are associated with fewer costs related to development, thus presenting attractive cost-savings to both payers and patients. The emergence of biosimilar agents for inflammatory conditions necessitates that pharmacists and managed care professionals share real-world safety and efficacy data to promote their proper use, decrease costs, improve outcomes, and increase patient access. To reduce barriers to the effective uptake of biosimilars, managed care professionals must work with clinicians to implement systems that incorporate biosimilars into clinical pathways. Managed care incentive and management programs with the potential to boost biosimilar use for inflammatory conditions within managed care organizations will be explored. 
 
Target audience:&nbsp;Managed care pharmacists 
Type of activity:&nbsp;Application 
Release date: October 9, 2020 
Expiration date: October 9, 2021 
Time to complete activity: 1.0 hour 
Fee: Free 
 
Educational Objectives 
At the completion of this activity, participants will be able to: 

<ul>
	<li>Identify the patient populations with rheumatic and inflammatory disease and consider the biologic costs associated with pharmacologic treatment.</li>
	<li>Analyze the most up-to-date clinical evidence and real-world data demonstrating efficacy of inflammatory biosimilars.</li>
	<li>Demonstrate how to develop evidence-based managed care protocols that will save costs and increase access to effective treatment for patients who require treatment of inflammatory conditions.</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-298-H01-P. The activity is available for CE credit through October 9, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
&nbsp;
<hr /> 
Disclosures 
 
Sonia T. Oskouei, PharmD, BCMAS, DPLA, has no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times&nbsp;Continuing Education&trade;&nbsp;Planning Staff&nbsp;&ndash; Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Brianna Schauer, MBA; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this internet CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Biosimilars: A Managed Care Update of Real-World Evidence and Cost-Savings Data When Treating Inflammatory Conditions

<img src="https://s3.amazonaws.com/ptce/_media/_image/Biosimilars_logo.png" style="max-width:350px; width:100%" />

<h2 style="text-align:center">Use of Oncology Supportive Care Biosimilars During COVID-19: Clinical Strategies for Pharmacists</h2>

<div style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px; text-align:center">This activity is supported by an educational grant from 
Coherus Biosciences, Inc.</div>
 
Faculty 
 
Julianna Merten, PharmD, BCPS, BCOP 
Ambulatory Care Pharmacist 
Assistant Professor of Pharmacy 
College of Medicine 
Mayo Clinic 
Rochester, Minnesota 
Chimeric Medical Communications, LLC 
Saint Ansgar, Iowa 
&nbsp;
<hr /> 
Activity Overview 
With the widespread availability of oncology biosimilar products in clinical practice, pharmacists are often involved with promoting standard practices for their patients and the development of patient-specific treatment plans. Although national guidelines provide recommendations for appropriate use of oncology supportive care growth factors and biosimilars, the COVID-19 pandemic has necessitated changes in practice. This activity will provide pharmacists with an overview of growth factor biosimilars, with an emphasis on use for neutropenia and alternative approaches during the pandemic. Strategies for safe use in clinical practice and economic considerations will be addressed, with a goal of providing pharmacists with an understanding of biosimilars and the emerging changes in practice during COVID-19. 
 
Educational Objectives 
At the completion of this activity, the participant will be able to:

<ul>
	<li>Examine current oncology supportive care biosimilars and the place in clinical practice for granulocyte colony-stimulating factors</li>
	<li>Investigate current challenges surrounding supportive care biosimilars in clinical practice during the COVID-19 pandemic</li>
	<li>Identify safe practices and strategies for appropriate use of supportive care biosimilars in clinical practice during the COVID-19 pandemic</li>
	<li>Explain economic considerations of supportive care agents</li>
</ul>
 
Target Audience:&nbsp;Oncology, health-system, managed care, specialty, and retail pharmacists 
Activity Type:&nbsp;Application 
Release Date:&nbsp;July 15, 2020 
Expiration Date:&nbsp;July 15, 2021&nbsp;&nbsp; 
Estimated Time to Complete Activity:&nbsp;2 hours 
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-20-171-H01-P. The activity is available for CE credit through July 15, 2021. &nbsp;&nbsp;&nbsp;&nbsp; 
 
 
Instructions for Earning Credit 
 
If you successfully complete the posttest and the evaluation form, this information will be uploaded into CPE Monitor. You must complete these steps before the activity expires in order to receive your credit. You may view your credit within 48 hours at&nbsp;www.mycpemonitor.net. 
 
NOTE:&nbsp;Your CE credit will be automatically uploaded to CPE Monitor. Please ensure that your&nbsp;Pharmacy Times&reg; account is updated with your NABP e-profile ID number and your date of birth. Participation data will not be uploaded into CPE Monitor if you do not have your NABP e-profile ID number and date of birth entered into your profile on&nbsp;www.pharmacytimes.org. 
&nbsp;
<hr /> 
Disclosures 
The following contributors have no relevant financial relationships with commercial interests to disclose: 
 
Faculty 
Julianna Merten, PharmD, BCPS, BCOP 
 
Pharmacy Times&nbsp;Continuing Education&trade; Planning Staff: 
Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Kelly McCormick; Susan Pordon; and Brianna Winters 
 
Pharmacy Times&reg;&nbsp;Editorial Staff 
Davy James 
 
Anonymous peer reviewers were part of the content validation and conflict resolution and have no relevant financial relationships with commercial interests to disclose.&nbsp; 
 
Educational Disclaimer 
Continuing professional education (CPE) activities sponsored by&nbsp;Pharmacy Times&nbsp;Continuing EducationTM&nbsp;are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this Internet CPE activity, please contact: 
ceinfo@pharmacytimes.com 
Privacy Policy and Terms of Use information: 
<a href="https://www.pharmacytimes.org/terms">https://www.pharmacytimes.org/terms</a> 
&nbsp;

Use of Oncology Supportive Care Biosimilars During COVID-19: Clinical Strategies for Pharmacists

<h2>Incorporating the Use of Biosimilars into Clinical Practice: Opportunities for Pharmacists to Intervene</h2>
This activity is supported by MJH Life Sciences, the parent company of Pharmacy Times&reg; and PTCE. 
 
Faculty Presenters 
 
Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP 
Clinical Coordinator 
Hematology/Oncology Department of Pharmacy 
University of Arizona Cancer Center 
Tucson, Arizona 
&nbsp;
<div style="margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in; text-align:center">
<hr /></div>
 
Program Description 
Biologics accounted for 22% of newly approved drugs between 2008 and 2017. However, biologics are some of the most expensive therapeutic agents, and these high costs are the main barrier preventing access of these agents for payers and patients. To address this concern, manufacturers have begun to apply for approval and develop biosimilars of reference biologics. There are currently 28 biosimilar agents that have been approved by the FDA since 2015, and 16 have launched in the US marketplace, especially with significant roles in oncology and rheumatic diseases. With additional biosimilar agents on the horizon, pharmacists must be familiar with the regulations governing development and approval of these agents, the concept of interchangeability, and particular indications of these biosimilar agents. 
 
Target Audience:&nbsp;Pharmacists practicing in community and health-system environments 
Type of Activity:&nbsp;Knowledge 
Release Date: July 10, 2020 
Expiration Date: July 10, 2021 
Fee: Free 
 
Educational Objectives

<ul>
	<li>Review the approval process and required nomenclature for biosimilars as well as the differences between biosimilars and biologics</li>
	<li>Outline the safety, efficacy, and role of biosimilars in the treatment of inflammatory and oncology conditions compared with their corresponding biologic products</li>
	<li>Recognize the role of the pharmacist in augmenting the use of biosimilars via educating both prescribers and patients on the potential clinical and economic advantages of biosimilars</li>
</ul>
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" />Pharmacy Times&nbsp;Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number 0290-0000-20-191-H03-P. The activity is available for CE credit through July 10, 2021. 
 
 
Instructions for Completing the Activity and Receiving CPE Credit 
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date. 
 
Disclosures 
 
Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP, has the following relevant financial relationships with commercial interests to disclose: 
Consultant: Pfizer 
Speakers Bureau: Coherus 
 
Pharmacy Times Continuing Education&trade; Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no financial relationships with commercial interests to disclose. 
 
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. 
 
Activity Disclaimer 
Pharmacy Times&nbsp;Continuing Education&trade; (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation. 
 
Educational Disclaimer 
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources. 
 
For questions about this live CPE activity, please contact: 
<a href="mailto:ceinfo@pharmacytimes.com">ceinfo@pharmacytimes.com</a> 
Privacy Policy and Terms of Use Information: 
<a href="http://www.pharmacytimes.org/terms">www.pharmacytimes.org/terms</a> 
&nbsp;

Incorporating the Use of Biosimilars into Clinical Practice: Opportunities for Pharmacists to Intervene

This activity is supported by an educational grant from Daiichi Sankyo, Inc.
<h2>An American Journal of Managed Care Supplement: Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer</h2>
FACULTY 
 
Jeremy Whalen, PharmD, BCOP 
Specialty Clinical Program Director of Oncology 
Prime Therapeutics 
Eagan, Minnesota 
 
Sandra Cuellar, PharmD, BCOP 
Clinical Associate Professor 
Department of Pharmacy Practice 
University of Illinois at Chicago &ndash; College of Pharmacy 
Chicago, Illinois 
 
MEDICAL WRITING &amp; EDITORIAL SUPPORT 
Thomas J. Cook, PhD 
Freelance Medical Writer 
Stewartsville, New Jersey 
 
Debra Gordon, MS 
GordonSquared, Inc 
Highland Park, Illinois 
 
Intended Audience 
Pharmacists and managed care professionals 
 
Activity Overview 
This activity will inform pharmacists and managed care professionals about the challenges to the increasing availability of trastuzumab biosimilars and other human epidermal growth factor receptor 2 (HER2)-targeted therapies, including HER2 antibody&ndash;drug conjugates. The activity will review aspects of FDA drug approval processes by comparing the regulatory pathways of small-molecule generics and biosimilars. Challenges to the adoption of biosimilars, with an emphasis on trastuzumab, will be discussed. This supplement was developed with the goal of providing pharmacists and managed care pharmacists with an understanding of the landscape of current and emerging availability of trastuzumab biosimilars and other HER2-directed therapies to treat HER2-positive&nbsp;breast cancer, with a focus on considerations that would assist in developing managed care strategies to optimize patient outcomes. 
 
Educational Objectives 
Upon completion of this activity, participants will be able to:
<ul>
	<li>Compare the regulatory pathway for FDA approval of biosimilar products with that of small-molecule generic products.</li>
	<li>Identify challenges to evidence-based adoption of trastuzumab biosimilars and other HER2-targeted therapies.</li>
	<li>Compare trastuzumab biosimilars and HER2 antibody&ndash;drug conjugates for HER2-positive breast cancer and assess their role in breast cancer treatment.</li>
	<li>Incorporate trastuzumab biosimilars and HER2 antibody&ndash;drug conjugates into formulary discussions, clinical care plans and processes, and educational initiatives for healthcare providers and patients.</li>
</ul>
Release date: February 28, 2020 
Expiration date: March 16, 2021 
Estimated time to complete activity: 2.0 hours 
Type of activity: Application 
Medium: Print with Internet-based posttest, evaluation, and request for credit 
Fee: Free 
 
Accreditation Statement 
 
<img alt="acpe" src="https://ptce.s3.amazonaws.com/_media/_eblast/ACPE_Large.jpg" style="float:left; height:59px; width:60px" /> &nbsp;Pharmacy Times Continuing Education&trade; is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-20-062-H03-P. The activity is available for CE credit through March 16, 2021. 
 
 
 
FACULTY DISCLOSURES 
Sandra Cuellar, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

<ul>
	<li>Consultancies or advisory boards: Amgen, Coherus, Eisai</li>
	<li>Lecture fees: Eisai, Genentech</li>
	<li>Spouse: employee of AstraZeneca</li>
</ul>
 
Jeremy Whalen, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose. 
 
 
MEDICAL WRITING &amp; EDITORIAL SUPPORT DISCLOSURES 
Thomas J Cook, PhD, and Debra Gordon, MS, have no relevant financial relationships with commercial interests to disclose. 
 
The American Journal of Managed Care&reg; Publishing Staff: Ida Delmendo, Ted Pigeon, Angelia Szwed, Monica Tran, Elizabeth Kukielka, and Andrea Szeszko have no relevant financial relationships with commercial interests to disclose. 
 
Pharmacy Times Continuing Education&trade; Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP; Nicole Grassano; Olivia Mastrodonato; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose. 
 
Disclosure Policy 
According to the disclosure policy of The American Journal of Managed Care&reg; and Pharmacy Times Continuing Education&trade;, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education&trade; to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. 
 
Disclosure of Unapproved/Off-Label Use 
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products. 
 
The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient&rsquo;s medical condition. 
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care&reg;, Pharmacy Times Continuing Education&trade;, or any of the companies that provided commercial support for this CE activity. 
 
Signed disclosures are on file at the office of The American Journal of Managed Care&reg;, Cranbury, New Jersey. 
&nbsp;

An American Journal of Managed Care Supplement: Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer